Consensus Sensei Biotherapeutics, Inc.

Equities

SNSE

US81728A1088

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
1.02 ^USD	+1.99%		+5.15%	+47.40%

Apr. 24	Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting	CI
Apr. 04	Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of Vista Within the Tumor Microenvironment	CI

Evolution of the average Target Price on Sensei Biotherapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

9d52305f18ce.y_kF23OeEdrJpZTON0qd-L8HgvWkGdDCnNilluRSwJY.vs59lkfWPIia0Ky3di_Lk91v9aL0SYOs67D8rpw1lKL_nFWuHa5Js6vhwQ~ac6ab4e158e2bc04479de607858a24ac

Analyst Recommendations on Sensei Biotherapeutics, Inc.

HC Wainwright Initiates Sensei Biotherapeutics With Buy Rating, Price Target is $4	Dec. 04	MT
Citigroup Initiates Sensei Biotherapeutics at Buy Rating	22-12-13	MT
SENSEI BIOTHERAPEUTICS : Mixed Q3; but cash cushion remains intact	22-11-10
Oppenheimer Upgrades Sensei Biotherapeutics to Outperform From Perform; Price Target is $5	22-10-03	MT
SENSEI BIOTHERAPEUTICS : Decent Q2; aided further by improving sentiment for Biotechs	22-08-10
Factoring in recent change of priorities (Sensei Biotherapeutics)	22-05-17	AL
Investment continues amidst various market challenges (Sensei Biotherapeutics)	22-05-13	AL
SENSEI BIOTHERAPEUTICS : Investment continues amidst various market challenges	22-05-13
Berenberg Bank Adjusts Sensei Biotherapeutics Price Target to $6 From $12, Maintains Hold Rating	22-04-01	MT
SENSEI BIOTHERAPEUTICS : Market sentiment continues to outweigh on-track clinical progress	22-03-14
Piper Sandler Adjusts Sensei Biotherapeutics' Price Target to $10 from $12, Keeps Overweight Rating	22-03-10	MT
Berenberg US CEO Virtual Conference	21-11-09	FA
Sensei Biotherapeutics to Participate in the Berenberg Virtual U.S. CEO Conference on Tuesday, November 9, 2021	21-11-03	AQ
SENSEI BIOTHERAPEUTICS : After SNS-301 setback, focus shifts to other programmes	21-08-09
SENSEI BIOTHERAPEUTICS : Piper Sandler Adjusts Price Target on Sensei Biotherapeutics to $12 From $25, Maintains Overweight Rating	21-07-06	MT
SENSEI BIOTHERAPEUTICS : SNS-301 programme scrapping casts major uncertainty	21-07-02
SENSEI BIOTHERAPEUTICS : Berenberg Downgrades Sensei Biotherapeutics to Hold from Buy, Sets $12 Price Target	21-07-01	MT
SENSEI BIOTHERAPEUTICS : Oppenheimer Downgrades Sensei Biotherapeutics to Perform From Outperform, Removes $36 PT	21-06-29	MT
SENSEI BIOTHERAPEUTICS : Citigroup Adjusts Price Target on Sensei Biotherapeutics to $14 From $30, Reiterates Buy Rating	21-06-29	MT
SENSEI BIOTHERAPEUTICS : After a reassuring Q1, focus shifts to phase I/II trial readout of SNS-301	21-05-14
SENSEI BIOTHERAPEUTICS : A personalised immuno-oncology cocktail in the making	21-04-12
SENSEI BIOTHERAPEUTICS : Oppenheimer Initiates Coverage on Sensei Biotherapeutics at Outperform Rating, Sets Price Target at $36	21-03-01	MT
SENSEI BIOTHERAPEUTICS : Berenberg Starts Sensei Biotherapeutics at Buy With $27 Price Target	21-03-01	MT
SENSEI BIOTHERAPEUTICS : Citigroup Starts Sensei Biotherapeutics at Buy With $30 Price Target	21-03-01	MT
SENSEI BIOTHERAPEUTICS : Piper Sandler Starts Sensei Biotherapeutics at Overweight With $25 Price Target	21-03-01	MT